⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25489700 | 1.00 | — | — | |
| SCHEMBL1547308 | 1.00 | — | — | |
| SCHEMBL24350584 | 0.80 | ALPL (0.39) | — | |
| SCHEMBL20353363 | 0.75 | — | — | |
| SCHEMBL11241722 | 0.75 | — | — | |
| SCHEMBL25881106 | 0.75 | — | — | |
| SCHEMBL24251344 | 0.75 | — | — | |
| SCHEMBL25165219 | 0.75 | — | — | |
| SCHEMBL6165879 | 0.75 | ALPL (0.33) | — | |
| SCHEMBL25548549 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4269402-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| US-20230210852-A1 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | MEDIC LIFE SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2023014817-A1 | COMPOSITIONS AND METHODS FOR TREATING LYMPHOMAS WITH A CDK7 INHIBITOR IN COMBINATION WITH A BTK INHIBITOR | SYROS PHARMACEUTICALS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022134641-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 湃隆生物科技有限公司（香港） | 2022-06-30 | — | — | WO | disclosed |
| WO-2022082056-A1 | DOSING REGIMENS FOR CYCLIN‑DEPENDENT KINASE 7 (CDK7) INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2020140052-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. (US) | 2020-07-02 | — | — | WO | disclosed |